ImmunoGen has entered a licensing聽聽through which Eli Lilly and Company has obtained exclusive rights for the research, development and marketing of antibody-drug conjugates (ADCs).
These ADCs will be directed to targets chosen by Lilly based on the new camptothecin technology of ImmunoGen.
According to the international, multi-year definitive deal, ImmunoGen holds complete rights to the camptothecin platform for all targets that are not selected under the Lilly licence.
ImmunoGen is eligible for an upfront payment of $13m from Lilly for the preliminary targets opted by the latter.聽
Furthermore, Lilly has the option to select a predetermined number of additional targets for which ImmunoGen is entitled to a further $32.5m in exercise fees if Lilly licenses all the targets.聽
ImmunoGen could receive up to $1.7bn in potential target programme exercise fees and milestone payments on meeting development, regulatory and commercial goals that are pre-specified.聽
Lilly will also make tiered royalty payments to ImmunoGen as a percentage of global commercial sales.
In addition, Lilly will handle complete expenses linked to the research and development of the ADCs.
ImmunoGen senior vice-president and chief business officer Stacy Coen said: 鈥淟illy has a proven track record of bringing transformative oncology medicines to market and we are pleased that they selected our novel camptothecin technology to integrate with their efforts to develop next-generation ADCs.聽
鈥淭his licensing agreement demonstrates ImmunoGen鈥檚 continued innovation in ADCs, creates value from our intellectual property around a proprietary platform and further enhances our ability to re-invest in our business as we build out our pipeline and accelerate our transformation into a fully-integrated oncology company.鈥�
A crucial class of anticancer drugs, Camptothecins act on Type I topoisomerase.
Earlier, the US Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Lilly鈥檚 bebtelovimab for the treatment of Covid-19.
